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Background. Allergic reactions to cisplatin are not uncommon situation with incidence of 5-20%. In 
general, allergic reactions to cisplatin is a type 1 hypersensitivity with manifestations of itching, redness, 
papules, urticaria, chest pain, and anaphylactic symptoms. Desensitization methods are needed for patients 
who have no alternative medication.
Case Report. A 59-year-old woman with nasopharyngeal carcinoma experienced urticaria because of cisplatin 
in her fi rst-cycle of chemotherapy. In second cycle chemotherapy desensitization program was applied using 
a 12-step Castell protocol. We measured vital signs and symptoms every 15 minutes. Administration of 
cisplatin was completed in 2 hours and the patient tolerated whole program very well.
Discussion. Risk factors of hypersensitivity to cisplatin includes age <70 years, previous allergy history, 
history of carboplatin use with dose >650 mg, mutation of BRACA1/2 gene, and administration of combined 
regimens with taxane groups or liposomal inhibitor. Desensitization uses 3 solutions with 12 steps. Solution 
1 is 100 times the dilution of the target dose. Solution 2 is 10 times the dilution of the target dose and 
solution 3 use the appropriate target dose. Each solution is administered for 15 minutes using an infusion 
pump. Strict monitoring of vital signs and patient symptoms are done every 15 minutes during the program.
Conclusion. Doctors should be aware of allergies to cisplatin. Currently the allergic reaction to cisplatin 
can be overcome using desensitization method when no alternative drug is not available.
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Background
Cisplatin is a chemotherapy drug derived 
from platinum. It is fi rst introduced in 1980. 
Th is drug is widely used in cases of cancer 
in various tissue characteristics. Currently 
platinum-derived chemotherapy drugs have 
3 generations, namely  cisplatin, carboplatin 
and oxaliplatin.1 
Allergic reactions to the platinum 
group have been widely observed. However, 
cases from our local setting have never been 
comprehensively reported. Th e use of this drug 
requires consideration and strategy because 
the incidence of allergic reactions to platinum 
compounds is increasingly found. Replacing 
second-line drugs may not improve the disease, 
because until now the platinum group showed 
a remarkable  response to particular cancer. Th e 
use of platinum derivatives is increasing, so 
that the incidence of allergic cases against this 
group also increases. Th e incidence of allergy 
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to cisplatin is 5-20%, to carboplatin is 9-27%, 
and to oxaliplatin is 10-19%.2 Herewith 
we reported a successful administration of 
desensitization program to a patient with 
nasopharyngeal carcinoma experiencing 
allergic to cisplatin.
Case
A 59-year-old woman presented to our 
cancer clinic for second cycle of chemotherapy 
with docetaxel/cisplatin/5-fluorouracil 
regimen (TPF). The patient suffered from 
nasopharyngeal cancer and was planned to 
receive TPF regimen for 3 cycles with 21-
day interval and radiotherapy at the end of 
chemotherapy program. Dose of docetaxel was 
113.25 mg on day 1, cisplatin was 37.75 mg 
on days 1-4 and 5-fl urouracil 1132.5 mg on 
days 1-5. At the fi rst cycle of chemotherapy 
the patient experienced complaints of itching 
accompanied by small bumps and redness. 
These complaints occurred on the second 
day of chemotherapy. Upon consultation, 
suspected drug was cisplatin. Cisplatin was 
stopped while other drugs continued.
In the second cycle, the patient was 
planned to receive the same regimen because no 
drugs were considered as eff ective as cisplatin for 
nasopharyngeal cancer cases. Other platinum 
derivatives such as carboplatin and oxaliplatin 
also have potential for allergic reactions and 
according to clinical trials are more often used 
in cases other than nasopharyngeal cancer. 
Th erefore, desensitization to cisplatin drug was 
the only program that was worthtrying.
The patient's condition was generally 
good with stable vital signs. There were 
no complaints upon hospitalization. The 
desensitization program followed Castell's 
12-step procedure which included 3 solutions. 
According to the 12-step procedure castell 
cisplatin desensitization starts at step 5 and 
ignores steps 1 through step 4 so that only 2 
cisplatin solutions are needed (Figure 1). Th e 
fi rst solution was dissolved in a 0.9% NaCl 
0.9% physiological solution at a dose of 4 mg 
Figure 1 Castells 12-step cisplatin desensitization protocol6
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(concentration 0.04 mg / ml). The second 
solution was dissolved in 0.9 ml physiological 
solution NaCl as much as 100 ml at a dose of 
37.75 mg (concentration 0.38 mg).
Th e dosage of the drug is given according 
to the protocol and monitor of vital signs 
and complaints was done every 15 minutes. 
During administration of solution 1 to solution 
2, vital signs are stable and no complaints 
of itching, skin lesions, redness, nausea and 
vomiting to shortness of breath. In general 
the administration of cisplatin supposed to 
last for 1 hour according to the chemotherapy 
protocol. In this desensitization program the 
drug administration was fi nished in 2 hours.
Discussion
Chemotherapy drugs that are commonly 
reported to have allergic and anaphylactic 
reactions are platinum, taxan, anthracycline, 
asparginase and epipodofilotoxin groups. 
Manifestations include skin rash, cardiovascular 
symptoms, gastrointestinal symptoms and 
respiratory symptoms. Cancer incidence 
rate is increasing and so is the incidence of 
allergic symptom. Th e use of platinum group 
chemotherapy drugs is widely used because their 
eff ectiveness to induce curative or remission. 
Th e platinum group is drugs with a very small 
molecule that cannot induce an immunological 
response except after haptenisation. Mechanism 
of allergic reaction to cisplatin according to 
several studies will emerge after several cycles 
of chemotherapy exposure.3
Hypersensitivity reaction to cisplatin is 
a type 1 allergic reaction mediated by the role 
of IgE but in some cases reported to be caused 
by allergic reactions type 2, 3 and 4. Type 1 
allergic reactions have clinical manifestations 
such as itching, redness of the skin, papules 
or urtikaria, chest pain or even anaphylactic 
symptoms. Th e incidence of allergic reactions 
to cisplatin is 1-14%. Rare reports of severe 
allergic reactions were also observed. The 
median value of the appearance of symptoms 
is after chemotherapy for 6 cycles. Th e second 
generation platinum drug, carboplatin, has a 
higher incidence of 1-44%, while the third 
generation of this drug, oxaliplatin, has an 
incidence of 10-25%.4
Risk factors of allergic to cisplatin are 
as follows: age under 70 years, a history of 
previous allergies, a history of using carboplatin 
with doses >650 mg, a long period of time 
after last receiving platinum class drugs, 
mutations in the BRACA1 / 2 tumor inhibiting 
gene, receive chemotherapy of combination 
with taxans or liposomal inhibitors such as 
docorubicin.5 Th ere are several factors that 
can be used as predictor  of allergic reactions 
in the platinum group, the total cumulative 
dose of chemotherapy with the previous 
platinum group, high lymphocyte count  and 
low monocyte count.1
Th is patient had no alternative medicine 
besides cisplatin for achieving eff ectiveness to 
kill cancer cells. Th is stimulated desensitization 
program. According to the protocol introduced 
by Castell, desensitization uses 3 solutions 
with 12 steps. Solution 1 is dilution 100 times 
the target dose. Solution 2 is a dilution of 10 
times the target dose and solution 3 uses the 
target dose. Each solution was administered 
for 15 minutes using an infusion pump with 
the number of drops set according to protocol. 
Every 15 minutes strict monitoring including 
vital signs and assessment of patient complaints 
were carried out.6 If minor complaints presents, 
supportive drugs can be given. When severe 
complaints are observed, desensitization 
program needs to be terminated. 
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The implementation of cisplatin 
desensitization in this patient was successful 
and no complaints were found. The time 
needed for all processes were 2 hours and this 
time span was 1 hour longer than the time that 
should be used for cisplatin chemotherapy. 
However, a span of 2 hours remains eff ective in 
achieving the chemotherapy target. According 
to previous observation, the success rate of 
cisplatin desensitization is 100%.7 However, 
desensitization is temporary and only lasts 2-3 
times the half-life of the given drug. Th erefore, 
desensitization has to be administered in the 
next cycle of chemotherapy.8
Conclusion
In the situation where allergic stimulating 
drug cannot be substituted, desensitization 
is a considerable choice. Th e desensitization 
protocol that widely used is the 12 step 
protocol according to Castells. Th is protocol 
has been successfullyapplied in the present case.
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